Hormonal
Sibutramine, a serotonin-norepinephrine reuptake inhibitor, was withdrawn from the European market because it significantly increases the risk of serious cardiovascular events (stroke, heart attack, cardiac arrest) without providing sufficient long-term benefit.
Sibutramine is no longer available in Europe because it was found to increase the risk of heart attacks and strokes. If you encounter it in illicit products imported from outside the EU, be aware that these products may be unsafe and unregulated. Always inform your doctor about any weight loss supplements you are taking.
The study has concluded that sibutramine substantially increased the risk of cardiovascular incidents such as strokes, heart attacks and cardiac arrest... Based on the data from “SCOUT” study and other concerning reports, in 2010 EMA decided to suspend marketing authorizations for all medicines containing sibutramine throughout the European Union.
Why this rating
Based on the large randomized-controlled SCOUT trial and subsequent regulatory decisions.
Source
Review of upcoming and currently available anti-obesity drugs in Europe
Patryk Gryszkiewicz et al. · Journal of Education Health and Sport · 2023
DOI 10.12775/jehs.2023.30.01.005
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, sustained weight loss (5-20% body weight reduction) in adults with obesity or overweight with comorbidities, primarily by delaying gastric emptying and reducing central appetite signaling.Strong
- Orlistat, a lipase inhibitor, promotes modest weight loss (approx. 2-3 kg over 24 weeks) by blocking the absorption of dietary fat, but is associated with gastrointestinal side effects and potential fat-soluble vitamin deficiencies.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →